Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan versus placebo in C3 glomerulopathy or immune-complex membranoproliferative glomerulonephritis
NL-OMON55956Phase 3Recruiting
- Sponsor
- Apellis Pharmaceuticals
- Start
- Dec 2022
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Complement 3 glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) comparing Pegcetacoplan with Placebo (2 arms). Primary endpoint: Log-transformed ratio of uPCR at Week 26 compared with baseline. Started Dec 2022; status: recruiting.
02
Drugs
pegcetacoplan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on NL-OMON55956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55956.